Episode 062: “Paging Heme/Onc: Updates from ASCO 2023” - Management of NSCLC and KEYNOTE 671
This week’s episode is part 4 of 5 of a joint mini-series with our friends Two Onc Docs. In today’s episode, we will be recapping the current treatment of resectable NSCLC and discussing KEYNOTE 671, which was presented at ASCO 2023, looking at neoadjuvant chemo+immunotherapy followed by adjuvant immunotherapy. We also discuss the use of the “interaction test,” “multiplicity,” and it’s important role in understanding subgroup analyses.
Want to read the abstract for yourself? Click here!
Episode list:
Episode 1 covering covering rectal cancer & the PROSPECT Trial, as well as non-inferiority trials (released by Two Onc Docs): Click here
Episode 2 covering classical hodgkin’s lymphoma & SWOG 1826 as well as “p-values” and what it means when trials say “the median was not reached.” (released by The Fellow on Call): Click here
Episode 3 covering mRCC & the CONTACT03 Trial, as well as subgroup analysis (released by Two Onc Docs): Click here
The crew behind the magic:
Show outline: Vivek Patel
Production and hosts: Vivek Patel, Dan Hausrath, Karine Tawagi, Sam Armstrong
Editing: Vivek Patel
Social media management: Ronak Mistry
